Abstract 15929: Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States
Circulation(2019)
Abstract
Objective: Cardiovascular disease (CVD) is a major comorbidity among type 2 diabetes (T2D) patients, contributing significantly to total medical costs. An estimated 20% of people with T2D have CVD,...
MoreTranslated text
Key words
empagliflozin,cost-effectiveness cost-effectiveness,diabetes,second-line
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined